Pharmaceutical, odontological, cosmetic and dermatological compositions comprising addition salts of trichloroacetic acid, one or more hydroxyacids and optionally glutamic acid or glutamic acid bioisosteres and phytic acid are useful for the peeling of the gingival collar, skin peeling, for resurfacing, treating skin hyper pigmentation, control sebum production, acne, pore size reduction and reducing the appearance of scars without causing undesirable side effects and contrast in coloration of the treated skin, for stimulation of the fibroblasts, transdermal biorevitalization, stimulation of the production of new collagen, for aesthetic improvement, for skin lightening, skin beautifying, skin firming and skin rejuvenation.

Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: ##STR00001##
The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

Provided herein are methods for ameliorating the pathophysiology cysteine protease exotoxin comprising the step of administering to said individual an effective dose of an S-nitrosylating agent and an inositol phosphate or analog thereof.

Provided herein are methods for ameliorating the pathophysiology cysteine protease exotoxin comprising the step of administering to said individual an effective dose of an S-nitrosylating agent and an inositol phosphate or analog thereof.

Provided herein are methods for ameliorating the pathophysiology cysteine protease exotoxin comprising the step of administering to said individual an effective dose of an S-nitrosylating agent and an inositol phosphate or analog thereof.

The present invention relates to a method for treating Alzheimer's disease and 2,3-BPG metabolic disorder induced morbidities, comprising administrating a phthalide compound to an Alzheimer's disease patient or a patient having 2,3-BPG metabolic disorder induced morbidities, wherein the method is characterized by that the phthalide compound has the same effect as 2,3-BPG on modulating hemoglobin to reduce its oxygen affinity and can thus act as a 2,3-BPG functional substitute when the 2,3-BPG concentration is too low in the Alzheimer's disease patient or in the patient having 2,3-BPG metabolic disorder induced morbidities to maintain the normal oxygen release function of hemoglobin and therefore to maintain the normal cellular oxygenation level.

The present invention relates to a method for treating Alzheimer's disease and 2,3-BPG metabolic disorder induced morbidities, comprising administrating a phthalide compound to an Alzheimer's disease patient or a patient having 2,3-BPG metabolic disorder induced morbidities, wherein the method is characterized by that the phthalide compound has the same effect as 2,3-BPG on modulating hemoglobin to reduce its oxygen affinity and can thus act as a 2,3-BPG functional substitute when the 2,3-BPG concentration is too low in the Alzheimer's disease patient or in the patient having 2,3-BPG metabolic disorder induced morbidities to maintain the normal oxygen release function of hemoglobin and therefore to maintain the normal cellular oxygenation level.

The present invention relates to a method for treating Alzheimer's disease and 2,3-BPG metabolic disorder induced morbidities, comprising administrating a phthalide compound to an Alzheimer's disease patient or a patient having 2,3-BPG metabolic disorder induced morbidities, wherein the method is characterized by that the phthalide compound has the same effect as 2,3-BPG on modulating hemoglobin to reduce its oxygen affinity and can thus act as a 2,3-BPG functional substitute when the 2,3-BPG concentration is too low in the Alzheimer's disease patient or in the patient having 2,3-BPG metabolic disorder induced morbidities to maintain the normal oxygen release function of hemoglobin and therefore to maintain the normal cellular oxygenation level.

This invention relates to compositions containing combinations of a balanced phosphatidylcholine composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from an imbalance of fatty acids and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.